Solar Kitties | Energy & Longevity
Exploring alt-energy, longevity, biotech, and emerging markets through witty and rigorous independent, non-bias investment research.
- Top in Finance
- #20
- Subscribers
- 91K
- Paid subscribers
- 10+ paid
- Followers
- 91K
- Paid plan
- $9.99/mo
- Recommends
- 1
- Podcast
- Yes
rounded by Substack
other newsletters
What they write about
Independent research on biotech, longevity and energy infrastructure. Recurring subjects include medical devices and bioelectronic medicine, cancer and gene-editing therapeutics, FDA regulatory pathways, small-cap biotech consolidation, and high-voltage transmission and subsea grid projects.
- biotech
- longevity
- medical devices
- gene editing
- energy infrastructure
- small caps
Recent examples: Genflow Biosciences (GENFF): The Gene That Learned to Age Slowly · The Blood-Test Tollbooth: Why Payer Coverage, Not Scientific Promise, Will Decide Multi-Cancer Screening...
Written from Solar Kitties | Energy & Longevity’s own published post titles and openings in Sep 11, 2026. It describes the subjects the newsletter covers, not its views, and is not investment advice.
Growth history
Subscribers (thousands, nightly)
52K on Sep 10, 2026 → 91K on Sep 30, 2026
Followers (thousands, nightly)
Rank in Substack’s finance leaderboard: #20 today · #31 a week ago
Stats worth sharing
Tracked since Sep 10, 2026 — 21 daily snapshots so far. The card below is built from what we track and refreshes nightly.
- Percentile
- Top 4%
- Best rank seen
- #19
- Rank, 7 days
- +11 places
- Subscribers added
- +39K
- Followers added
- +39K
- Posts
- 7
- Reactions per post
- 24
- Reactions tracked
- 377
of 525 ranked finance newsletters
on Sep 28, 2026
since tracking began
since tracking began
last 30 days
average, recent posts
across 16 posts
Most-reacted post we have seen: The Subsea Grid & The Transcontinental Power Arbitrage — 42 reactions on Aug 11, 2026.
Recent posts
- Genflow Biosciences (GENFF): The Gene That Learned to Age Slowly
TL;DR New catalyst: Genflow says the randomized, blinded SLAB study met its primary endpoint , a reduction in biological age measured with the GRIM methylation clock . Detailed results are scheduled for the Animal Longevity Summit on October 2 , 2026. [ 1 ] What exists: 24 aged beagles in four arms: two naked plasmid-DNA dose groups, one AAV8 group, and a saline control. The dog product and the human lead use different delivery approaches. [ 1 ][ 2 ] What does not exist: published full canine endpoint tables, peer-reviewed evidence of canine lifespan extension, or a clinical demonstration…
- The Blood-Test Tollbooth: Why Payer Coverage, Not Scientific Promise, Will Decide Multi-Cancer Screening...
TL;DR The Problem Medicine routinely screens for only a handful of cancers. Multi-cancer early detection, or MCED , promises to search one blood sample for molecular signals from dozens more. But a screening result is not a diagnosis. Every positive can trigger imaging, specialist visits, biopsies and weeks of uncertainty—and payers must decide whether the entire chain improves health enough to justify its cost. The Solution MCED tests analyze fragments and chemical patterns shed into the bloodstream, then use algorithms to estimate whether cancer is present and where the signal may have…
- The Humanoid Gold Rush Has a Laundry Problem: 20 Million Robots Sold. Just 536 Could Care for You...
TL;DR The Problem The home is the most valuable—and least forgiving—worksite left to automate. It is cluttered, constantly changing, full of fragile objects, pets, children, stairs, private conversations and humans who do not behave like factory fixtures. A machine that is impressive on a stage can still be commercially useless if it breaks a wineglass, frightens a parent or needs a remote operator every time a sock disappears beneath a bed. The Solution Humanoid robots will not win the home by arriving as flawless mechanical butlers. They will enter through a wedge : one narrow, frequent and…
- The Trip Switch: How Non-Hallucinogenic Neuroplastogens Could Rewire Psychiatry—and Its Economics
TL;DR: The Solar Kitties Framework The Problem: Depression and related brain disorders are often treated with drugs that require chronic dosing, take weeks to work, and fail a meaningful share of patients; psychedelic therapies may act faster, but their acute psychoactive effects turn treatment into an expensive supervised event. The Solution: Non-hallucinogenic neuroplastogens are engineered to promote rapid structural and functional plasticity without producing a psychedelic experience—potentially converting a clinic-bound therapy into a conventional prescription medicine. The Opportunity…
- Why Bioelectronic Medicine Wins, One Indication at a Time...
Solar Kitties Research | Bioelectronic Medicine & Medical Devices The article’s clinical, operating, and regulatory milestones are indication-specific. The investable question is whether a device can turn a biological effect into a safe, reimbursed, repeatable treatment. TL;DR — The Solar Kitties Framework Problem - “Bioelectronic medicine” bundles together implanted stimulators, wearables, vagus-nerve therapies, spinal-cord systems, and laboratory interfaces. That makes for a handsome pitch deck—and a lousy investment category. Solution - Treat each program as an indication-specific…
- The IOU in the Gucci Blazer: What Tokenized Stocks Actually Own...
TL;DR -- The Solar Kitties Framework Problem “Tokenized stocks” are not one instrument. A wallet balance can represent registered ownership, a security entitlement, a synthetic linked product, or a contractual claim on an intermediary. Treating them as interchangeable is how investors buy the plumbing diagram instead of the plumbing. Solution The winning stack links a digital record to the official securityholder file, identity checks, transfer restrictions, corporate actions, custody, and delivery-versus-payment. The ledger is useful. The legal and operational control plane is indispensable…
- The Peripheral Rebellion: Why Parkinson’s Drug Discovery Is Moving Below the Neck
Solar Kitties Research | Parkinson’s, Microbiome & Precision Biotech In some patients, the actionable biology may begin far from the substantia nigra. The opportunity is not a miracle probiotic. It is a precision stack that can identify risk, control microbial chemistry, and finally tell researchers which patients might respond before they spend a decade—and a small country’s GDP—on the wrong trial. TL;DR: The Solar Kitties Framework The Problem: Parkinson’s is expanding faster than the old brain-only drug-development playbook can produce disease-modifying therapies, while biological…
- Merck’s Cancer Vaccine Is Only the Beginning - The Next Cancer Winner May Not Make Vaccines...
TL;DR — The Interception Thesis Problem: Cancer care still spends its largest checks after a tumor recurs, when the biology is hardest to control and the patient’s options are narrowest. Solution: Sequencing, circulating tumor DNA (ctDNA), individualized neoantigen design, therapeutic vaccination, checkpoint blockade, and RAS-targeted drugs are starting to operate as one precision loop. Opportunity: Merck and Moderna’s positive Phase 3 melanoma result validates the vaccine layer. Guardant validates the surveillance layer. Revolution Medicines validates the molecular-attack layer. The…
- The Subsea Grid & The Transcontinental Power Arbitrage
- How Epigenetic Reprogramming Just Crossed the Most Important Line in Biotech History...
- Small-Cap Biotech Outperformance: Rare Disease Innovation Fuels M&A Targets
Small-Cap Biotech Outperformance: Rare Disease Innovation Fuels M&A Targets The market’s obsession with pharmaceutical giants is obscuring a more interesting story. The real action - the kind that generates 10x returns, not 10% dividends - is happening in the labs of small-cap biotechs quietly rewriting the rules of human biology. TL;DR: The Solar Kitties Framework Core Thesis: Small-cap biotech companies focused on rare diseases, precision immunology, and novel therapeutic platforms are demonstrating significant clinical and financial momentum. The M&A environment is accelerating. The window…
- The Regulatory Fast Lane: How the FDA's Streamlined Pathways Are Unlocking In Vivo Gene Editing
TL;DR The Problem: Gene editing therapies face a regulatory paradox — the diseases they target are so rare that traditional two-trial approval standards are practically impossible to meet. The Signal: The FDA’s February 2026 “Plausible Mechanism Framework” draft guidance allows approval on a single well-controlled study with confirmatory evidence, specifically prioritising genome editing therapies. The Opportunity: The gene therapy market is compounding at ~19.8% annually toward $77.6 billion by 2035 , and the regulatory bottleneck just got significantly narrower. The Thesis: Beam…
← All trending finance newsletters
Data: Substack public leaderboards and publication archives, refreshed nightly, plus public beehiiv sitemaps and recommendation pages, refreshed weekly. Source for this page: Solar Kitties | Energy & Longevity. Subscriber counts are Substack’s own rounded public figures, so week-on-week changes move in steps. beehiiv audience sizes are self-reported by the publisher and are not verified. Last snapshot: Sep 30, 2026.